OLEMA PHARMACEUTICALS, INC. Payments to Acquire Marketable Securities
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Payments to Acquire Marketable Securities of $118.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2026-06-30 was $48.24M, a 46.79% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2026-03-31 was $69.94M, a 51.04% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2025-12-31 was $253.35M, a 33.89% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2025-09-30 was $71.65M, a 50.93% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2025 was $500.72M, a 26.78% increase from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2024 was $394.96M, a 54.51% increase from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2023 was $255.63M, a 19.64% increase from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2022 was $213.66M, a 56.12% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $48.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $118.18M 10-Q · filed 2026-08-10 | $371.53M derived: sum of 3 quarters · filed 2026-08-10 | $443.18M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $69.94M 10-Q · filed 2026-05-12 | $323.29M derived: sum of 2 quarters · filed 2026-05-12 | $394.94M derived: sum of 3 quarters · filed 2026-05-12 | $427.81M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $253.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $325.00M derived: sum of 2 quarters · filed 2026-03-16 | $357.87M derived: sum of 3 quarters · filed 2026-08-10 | $500.72M 10-K · filed 2026-03-16 |
| 2025-09-30 | $71.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $104.52M derived: sum of 2 quarters · filed 2026-08-10 | $247.37M 10-Q · filed 2025-11-10 | $436.60M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $32.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $175.72M 10-Q · filed 2026-08-10 | $364.95M derived: sum of 3 quarters · filed 2026-08-10 | $412.42M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $142.85M 10-Q · filed 2026-05-12 | $332.08M derived: sum of 2 quarters · filed 2026-05-12 | $379.56M derived: sum of 3 quarters · filed 2026-05-12 | $461.72M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $189.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $236.71M derived: sum of 2 quarters · filed 2026-03-16 | $318.87M derived: sum of 3 quarters · filed 2026-03-16 | $394.96M 10-K · filed 2026-03-16 |
| 2024-09-30 | $47.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $129.64M derived: sum of 2 quarters · filed 2025-11-10 | $205.73M 10-Q · filed 2025-11-10 | $290.64M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $82.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $158.25M 10-Q · filed 2025-08-11 | $243.17M derived: sum of 3 quarters · filed 2025-08-11 | $339.12M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $76.09M 10-Q · filed 2025-05-13 | $161.01M derived: sum of 2 quarters · filed 2025-05-13 | $256.96M derived: sum of 3 quarters · filed 2025-05-13 | $307.34M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $84.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $180.87M derived: sum of 2 quarters · filed 2025-03-18 | $231.25M derived: sum of 3 quarters · filed 2025-03-18 | $255.63M 10-K · filed 2025-03-18 |
| 2023-09-30 | $95.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $146.34M derived: sum of 2 quarters · filed 2024-11-12 | $170.71M 10-Q · filed 2024-11-12 | $215.20M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $50.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $74.76M 10-Q · filed 2024-08-06 | $119.25M derived: sum of 3 quarters · filed 2024-08-06 | $137.70M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $24.37M 10-Q · filed 2024-05-08 | $68.87M derived: sum of 2 quarters · filed 2024-05-08 | $87.31M derived: sum of 3 quarters · filed 2024-05-08 | $114.88M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $44.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $62.94M derived: sum of 2 quarters · filed 2024-03-11 | $90.51M derived: sum of 3 quarters · filed 2024-03-11 | $213.66M 10-K · filed 2024-03-11 |
| 2022-09-30 | $18.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $46.01M derived: sum of 2 quarters · filed 2023-11-07 | $169.17M 10-Q · filed 2023-11-07 | $189.12M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $27.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $150.72M 10-Q · filed 2023-08-08 | $170.68M derived: sum of 3 quarters · filed 2023-08-08 | $302.81M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $123.15M 10-Q · filed 2023-05-09 | $143.11M derived: sum of 2 quarters · filed 2023-05-09 | $275.25M derived: sum of 3 quarters · filed 2023-05-09 | $329.96M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $19.96M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $152.09M derived: sum of 2 quarters · filed 2023-03-09 | $206.80M derived: sum of 3 quarters · filed 2023-03-09 | $486.97M 10-K · filed 2023-03-09 |
| 2021-09-30 | $132.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $186.85M derived: sum of 2 quarters · filed 2022-11-08 | $467.01M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $54.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $334.87M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $280.16M 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |